ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
Based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s ENHERTU that showed clinically…